BioCentury | Jan 7, 2021
Finance
Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest
...its $56 million series A are Longwood Fund, Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises and DC Investment Partners...